News und Analysen
EQS-Adhoc: BB Biotech AG veröffentlicht Zwischenbericht
EQS-News: BB Biotech im Q1 2025: Portfoliofokus inmitten anhaltender Volatilität geschärft
EQS-News: Evotec verkündet starke Fortschritte in strategischer Kollaboration mit Bristol Myers Squibb im Bereich Protein Degradation
Hidden Gems: 3 Quiet Stocks With Loud Potential
Short-term volatility has been a hallmark of the market in 2025, but one way investors may be able to bypass this concern is by adopting a longer time horizon for their investments. After all, the
Evotec Aktie: Zwei-Säulen-Strategie beflügelt Wachstum!
– Evotec SE fokusiert sich auf Wirkstoffforschung und zeigt Weg zu profitablen Wachstum –…
Der Beitrag Evotec Aktie: Zwei-Säulen-Strategie beflügelt Wachstum! erschien zuerst auf kapitalmarktexperte
3 Under-the-Radar Healthcare Stocks Worth Adding to Your Watchlist
A few healthcare companies garner much of the attention in the sector. The list includes Eli Lilly, Johnson & Johnson, UnitedHealth Group, and several others. However, beyond those giants, there are
EQS-News: Evotec Appoints Dr. Ingrid Müller as Chief Operating Officer
CVS Health Just Got a $13 Billion Reprieve. Here's Why the Stock Could Keep Climbing.
In a matter of months, a key issue affecting CVS Health's (NYSE: CVS) performance has seemingly vanished. On April 7, the Centers for Medicare & Medicaid Services (CMS) finalized the amount by which
Why Intuitive Machines Stock Popped on Friday
Intuitive Machines (NASDAQ: LUNR) stock jumped 5.5% through 12:50 p.m. ET Friday on no specific news -- no specific news about Intuitive Machines, that is, or at least not yet.
Rather, investors in
EQS-News: Evotec Announces Fourth Quarter and Full-Year 2025 Results: Foundation for Profitable Growth
EQS-News: Evotec to Receive Approx. $100 Million as Part of Tubulis Acquisition
EQS-News: Evotec Nominates Dieter Weinand as Supervisory Board Chairman
Stock Market Today, April 6: Soleno Therapeutics Climbs After $2.9 Billion All-Cash Buyout Agreement
Soleno Therapeutics (NASDAQ:SLNO), a rare-disease drug developer, closed Monday at $52.26, up 32.31%. The stock’s move reflects Neurocrine Biosciences’ (NASDAQ:NBIX) $53-per-share all-cash
Why Soleno Therapeutics Stock Rocketed Higher on Monday
On news that Soleno Therapeutics (NASDAQ: SLNO) has agreed to be acquired, investors piled into the company's shares on Monday. This left the commercial-stage biotech with a juicy 32% gain on the
EQS-News: Evotec SE to Announce Fourth Quarter and Full-Year 2025 Results on April 8, 2026
EQS-News: Evotec Appoints Dr. Ashiq H. Khan as Chief Commercial Officer
Exelixis: A Strong Contender in the Cancer Drug Market
Explore the exciting world of Exelixis (NASDAQ: EXEL) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market
Why Agios Pharmaceuticals Stock Is Up More Than 21% Today
Drugmaker Agios Pharmaceuticals (NASDAQ: AGIO) is positioning to win the FDA's approval of its mitapivat as a treatment for sickle cell disease sooner than investors may have been expecting.
That's
Insider Sells AGIO Shares Worth $82,000 -- But Context Is Everything
Viswanadhan Krishnan, Chief Corporate Development and Strategy Officer at Agios Pharmaceuticals (NASDAQ:AGIO), reported the open-market sale of 2,959 shares of common stock for a total of roughly
Irresistible Change: How to Spot Real Growth
Phil Gilbert, serial entrepreneur and former general manager at IBM, joins this episode of Motley Fool Money to talk about his new book, Irresistible Change: A Blueprint for Earning Buy-In and
EQS-News: Just – Evotec Biologics Enters Project Agreement with BARDA to Optimize Biomanufacturing of Antibodies Against Ebola and Related Viruses
2 Healthcare Stocks to Buy Before They Get Bought Out
Abivax (NASDAQ: ABVX) and Nektar Therapeutics (NASDAQ: NKTR) aren't well-known companies, and they don't have track records of profitability yet. That's natural, as both are clinical-stage biotechs
Is Relay Therapeutics a Buy in 2026? One Institutional Investor Just Made a $6 Million Bet.
According to a Securities and Exchange Commission (SEC) filing dated Feb. 17, 2026, Nextech Invest, Ltd. bought 855,097 additional shares of Relay Therapeutics (NASDAQ:RLAY). The estimated
EQS-News: Evotec Receives $10 M Milestone from Bristol Myers Squibb Protein Degradation Collaboration for Clinical Study Initiation
Biotech Stock Still Up 700% Despite 30% Drop This Year as One Fund Discloses $9 Million Exit
On February 17, 2026, 5AM Venture Management reported selling its entire stake in Praxis Precision Medicines (NASDAQ:PRAX), an estimated $9.01 million trade based on last-disclosed position values.